Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC


Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Mitchell S. Cairo, MD, and Sergio Giralt, MD, experts on veno-occlusive disease
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic
Federico Cappuzzo, MD
Mitchell S. Cairo, MD, an expert on veno-occlusive disease